Jennifer Richer
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Triple Negative Breast Neoplasms | 14 | 2023 | 157 | 6.260 |
Why?
| Receptors, Androgen | 13 | 2023 | 132 | 5.370 |
Why?
| Breast Neoplasms | 43 | 2022 | 1872 | 4.220 |
Why?
| MicroRNAs | 17 | 2018 | 607 | 4.040 |
Why?
| Androgen Receptor Antagonists | 8 | 2021 | 30 | 2.560 |
Why?
| Gene Expression Regulation, Neoplastic | 34 | 2021 | 1147 | 2.390 |
Why?
| Anoikis | 7 | 2021 | 31 | 2.350 |
Why?
| Estrogen Receptor alpha | 6 | 2022 | 120 | 1.990 |
Why?
| Receptors, Progesterone | 24 | 2016 | 319 | 1.950 |
Why?
| Cell Line, Tumor | 36 | 2023 | 2751 | 1.930 |
Why?
| Phenylthiohydantoin | 6 | 2017 | 40 | 1.820 |
Why?
| Receptors, Estrogen | 14 | 2020 | 372 | 1.450 |
Why?
| Tryptophan Oxygenase | 3 | 2018 | 22 | 1.310 |
Why?
| Tryptophan | 2 | 2018 | 136 | 1.170 |
Why?
| Progesterone | 16 | 2014 | 232 | 1.060 |
Why?
| Ovarian Neoplasms | 4 | 2020 | 407 | 1.010 |
Why?
| Progestins | 6 | 2014 | 75 | 1.000 |
Why?
| Tamoxifen | 10 | 2016 | 192 | 1.000 |
Why?
| Neoplastic Stem Cells | 3 | 2017 | 331 | 0.910 |
Why?
| Epithelial Cells | 3 | 2022 | 961 | 0.900 |
Why?
| Ribonuclease III | 2 | 2016 | 33 | 0.900 |
Why?
| Drug Resistance, Neoplasm | 7 | 2020 | 638 | 0.890 |
Why?
| DEAD-box RNA Helicases | 2 | 2016 | 55 | 0.880 |
Why?
| Epithelial-Mesenchymal Transition | 5 | 2018 | 167 | 0.870 |
Why?
| Biomarkers, Tumor | 7 | 2021 | 1048 | 0.870 |
Why?
| Receptor, ErbB-2 | 4 | 2017 | 302 | 0.840 |
Why?
| Cell Proliferation | 14 | 2021 | 2194 | 0.840 |
Why?
| Gene Expression Profiling | 11 | 2018 | 1536 | 0.790 |
Why?
| Kallikreins | 1 | 2021 | 30 | 0.790 |
Why?
| Neoplasm Recurrence, Local | 6 | 2023 | 863 | 0.780 |
Why?
| Adipokines | 1 | 2021 | 43 | 0.780 |
Why?
| Prostate-Specific Antigen | 1 | 2021 | 151 | 0.740 |
Why?
| Endometrial Neoplasms | 6 | 2011 | 151 | 0.740 |
Why?
| Trophoblasts | 1 | 2022 | 162 | 0.730 |
Why?
| Membrane Transport Proteins | 1 | 2021 | 137 | 0.720 |
Why?
| RNA, Long Noncoding | 2 | 2022 | 157 | 0.720 |
Why?
| Transcription Factors | 13 | 2023 | 1528 | 0.710 |
Why?
| Cell Movement | 9 | 2020 | 867 | 0.710 |
Why?
| Immunohistochemistry | 8 | 2017 | 1642 | 0.710 |
Why?
| Transforming Growth Factor beta1 | 1 | 2021 | 156 | 0.690 |
Why?
| Androgen Antagonists | 3 | 2017 | 69 | 0.690 |
Why?
| Pulmonary Alveoli | 1 | 2022 | 376 | 0.690 |
Why?
| Alternative Splicing | 2 | 2018 | 187 | 0.680 |
Why?
| Mammary Glands, Animal | 4 | 2022 | 116 | 0.680 |
Why?
| Homeodomain Proteins | 5 | 2014 | 465 | 0.670 |
Why?
| Repressor Proteins | 6 | 2018 | 369 | 0.670 |
Why?
| Cell Cycle | 4 | 2021 | 546 | 0.650 |
Why?
| Female | 57 | 2023 | 59931 | 0.650 |
Why?
| Up-Regulation | 7 | 2020 | 820 | 0.620 |
Why?
| RNA Splicing Factors | 1 | 2018 | 50 | 0.620 |
Why?
| Mammary Neoplasms, Experimental | 3 | 2017 | 64 | 0.610 |
Why?
| Humans | 83 | 2023 | 115611 | 0.600 |
Why?
| Mice | 23 | 2021 | 15052 | 0.600 |
Why?
| Animals | 38 | 2022 | 32102 | 0.600 |
Why?
| Xenograft Model Antitumor Assays | 8 | 2021 | 704 | 0.590 |
Why?
| Nitriles | 6 | 2017 | 152 | 0.560 |
Why?
| Benzamides | 6 | 2017 | 168 | 0.560 |
Why?
| Lactation | 2 | 2022 | 149 | 0.560 |
Why?
| Carcinoma, Endometrioid | 2 | 2008 | 47 | 0.560 |
Why?
| Gonadal Steroid Hormones | 1 | 2018 | 124 | 0.550 |
Why?
| Lipogenesis | 1 | 2016 | 57 | 0.540 |
Why?
| Paclitaxel | 3 | 2017 | 192 | 0.540 |
Why?
| Antineoplastic Agents | 6 | 2018 | 1893 | 0.530 |
Why?
| Antibody Specificity | 1 | 2016 | 176 | 0.530 |
Why?
| Receptor, trkB | 2 | 2012 | 28 | 0.510 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2015 | 39 | 0.510 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 5 | 0.490 |
Why?
| Apoptosis | 11 | 2020 | 2377 | 0.480 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2017 | 362 | 0.470 |
Why?
| RNA Interference | 3 | 2015 | 438 | 0.470 |
Why?
| Antibodies | 1 | 2016 | 374 | 0.460 |
Why?
| Metformin | 2 | 2014 | 278 | 0.460 |
Why?
| Receptors, Steroid | 2 | 2010 | 52 | 0.450 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2018 | 693 | 0.440 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1361 | 0.430 |
Why?
| Gene Expression Regulation | 8 | 2016 | 2353 | 0.430 |
Why?
| Kynurenine | 3 | 2018 | 80 | 0.430 |
Why?
| Chromatin | 1 | 2016 | 429 | 0.430 |
Why?
| Neoadjuvant Therapy | 2 | 2020 | 301 | 0.420 |
Why?
| Signal Transduction | 17 | 2015 | 4541 | 0.410 |
Why?
| Disease Progression | 6 | 2018 | 2418 | 0.400 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2012 | 61 | 0.400 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 45 | 0.390 |
Why?
| Antineoplastic Agents, Hormonal | 5 | 2020 | 139 | 0.390 |
Why?
| Endometrium | 2 | 2008 | 59 | 0.370 |
Why?
| Transcriptional Activation | 5 | 2017 | 340 | 0.360 |
Why?
| Mice, SCID | 4 | 2020 | 321 | 0.360 |
Why?
| Neoplasms | 5 | 2022 | 2118 | 0.340 |
Why?
| Estradiol | 6 | 2016 | 452 | 0.340 |
Why?
| Cell Transformation, Neoplastic | 1 | 2012 | 314 | 0.340 |
Why?
| Tubulin Modulators | 1 | 2009 | 9 | 0.330 |
Why?
| 3' Untranslated Regions | 4 | 2014 | 136 | 0.330 |
Why?
| Cadherins | 4 | 2012 | 175 | 0.330 |
Why?
| Cells | 1 | 2009 | 22 | 0.330 |
Why?
| Uterine Neoplasms | 2 | 2008 | 73 | 0.330 |
Why?
| Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 23 | 0.330 |
Why?
| Dirofilaria immitis | 3 | 2010 | 3 | 0.310 |
Why?
| Mice, Nude | 5 | 2017 | 639 | 0.300 |
Why?
| Feedback, Physiological | 2 | 2021 | 73 | 0.290 |
Why?
| Cell Nucleus | 5 | 2017 | 553 | 0.290 |
Why?
| Trastuzumab | 2 | 2017 | 89 | 0.290 |
Why?
| Microtubules | 1 | 2009 | 238 | 0.280 |
Why?
| Transfection | 5 | 2012 | 866 | 0.280 |
Why?
| MCF-7 Cells | 3 | 2016 | 105 | 0.280 |
Why?
| Epidermal Growth Factor | 4 | 2005 | 161 | 0.270 |
Why?
| Cell Differentiation | 1 | 2012 | 1700 | 0.250 |
Why?
| Anilides | 2 | 2016 | 67 | 0.250 |
Why?
| Mice, Inbred NOD | 3 | 2020 | 560 | 0.240 |
Why?
| Down-Regulation | 6 | 2016 | 601 | 0.240 |
Why?
| Gene Expression | 4 | 2020 | 1436 | 0.230 |
Why?
| Microarray Analysis | 2 | 2016 | 119 | 0.230 |
Why?
| Lung Neoplasms | 1 | 2017 | 2207 | 0.230 |
Why?
| Molecular Targeted Therapy | 2 | 2018 | 348 | 0.230 |
Why?
| Pharmacology, Clinical | 1 | 2023 | 8 | 0.220 |
Why?
| Mutation | 5 | 2022 | 3364 | 0.220 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 746 | 0.220 |
Why?
| Epigenesis, Genetic | 2 | 2018 | 526 | 0.210 |
Why?
| Tumor Cells, Cultured | 11 | 2020 | 850 | 0.200 |
Why?
| Neoplasm Invasiveness | 3 | 2015 | 445 | 0.200 |
Why?
| Mammary Glands, Human | 2 | 2014 | 60 | 0.200 |
Why?
| Milk Proteins | 2 | 1999 | 36 | 0.200 |
Why?
| NF-E2-Related Factor 2 | 1 | 2022 | 73 | 0.200 |
Why?
| Estrogens | 3 | 2020 | 315 | 0.200 |
Why?
| Epithelium | 1 | 2022 | 297 | 0.190 |
Why?
| Mice, Transgenic | 2 | 2017 | 1970 | 0.190 |
Why?
| Neoplastic Cells, Circulating | 1 | 2022 | 59 | 0.190 |
Why?
| Promoter Regions, Genetic | 6 | 2014 | 1122 | 0.190 |
Why?
| Tumor Microenvironment | 2 | 2022 | 431 | 0.190 |
Why?
| DNA-Binding Proteins | 6 | 2018 | 1316 | 0.190 |
Why?
| Neoplasms, Second Primary | 1 | 2022 | 91 | 0.190 |
Why?
| Semaphorins | 1 | 2020 | 21 | 0.180 |
Why?
| Neoplasm Proteins | 2 | 2018 | 385 | 0.180 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2020 | 40 | 0.180 |
Why?
| Respiratory Mucosa | 1 | 2022 | 258 | 0.180 |
Why?
| NF-kappa B | 2 | 2015 | 639 | 0.180 |
Why?
| Transcription, Genetic | 9 | 2012 | 1310 | 0.180 |
Why?
| Immune Tolerance | 1 | 2022 | 332 | 0.180 |
Why?
| Androgens | 1 | 2021 | 165 | 0.180 |
Why?
| Epoxy Compounds | 1 | 2020 | 31 | 0.180 |
Why?
| Pregnancy | 3 | 2022 | 5550 | 0.170 |
Why?
| Gene Knockdown Techniques | 2 | 2020 | 302 | 0.170 |
Why?
| RNA, Messenger | 7 | 2011 | 2574 | 0.170 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2020 | 43 | 0.170 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2020 | 44 | 0.170 |
Why?
| STAT5 Transcription Factor | 3 | 2014 | 44 | 0.170 |
Why?
| Chemotherapy, Adjuvant | 1 | 2020 | 334 | 0.170 |
Why?
| RNA, Small Interfering | 3 | 2020 | 544 | 0.160 |
Why?
| Prolactin | 1 | 1998 | 95 | 0.160 |
Why?
| Gene Amplification | 1 | 2018 | 96 | 0.160 |
Why?
| Antigens, CD | 1 | 2020 | 442 | 0.150 |
Why?
| Immunoblotting | 3 | 2010 | 281 | 0.150 |
Why?
| Binding Sites | 5 | 2016 | 1177 | 0.150 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 111 | 0.150 |
Why?
| Endometrial Hyperplasia | 2 | 2008 | 15 | 0.150 |
Why?
| Fatty Acids | 1 | 2020 | 386 | 0.140 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 2017 | 41 | 0.140 |
Why?
| Cluster Analysis | 4 | 2008 | 465 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 63 | 0.140 |
Why?
| Histone Acetyltransferases | 3 | 2006 | 50 | 0.140 |
Why?
| Dihydrotestosterone | 1 | 2017 | 39 | 0.140 |
Why?
| Immunity, Cellular | 1 | 2018 | 262 | 0.140 |
Why?
| Neoplasm Transplantation | 2 | 2014 | 235 | 0.140 |
Why?
| Heterografts | 1 | 2017 | 119 | 0.140 |
Why?
| Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.140 |
Why?
| Cyclohexanes | 1 | 2016 | 22 | 0.140 |
Why?
| Placenta | 1 | 2022 | 624 | 0.140 |
Why?
| Tumor Suppressor Proteins | 2 | 2014 | 286 | 0.140 |
Why?
| Carcinogenesis | 1 | 2018 | 178 | 0.140 |
Why?
| Trans-Activators | 4 | 2006 | 370 | 0.130 |
Why?
| Ovary | 1 | 2017 | 190 | 0.130 |
Why?
| Hyaluronan Receptors | 2 | 2014 | 91 | 0.130 |
Why?
| Killer Cells, Natural | 1 | 2018 | 383 | 0.130 |
Why?
| Transplantation, Heterologous | 2 | 2014 | 187 | 0.130 |
Why?
| Phosphoproteins | 2 | 2008 | 304 | 0.120 |
Why?
| Neoplasm Metastasis | 2 | 2015 | 526 | 0.120 |
Why?
| Drug Delivery Systems | 1 | 2017 | 301 | 0.120 |
Why?
| Hormones | 1 | 2015 | 132 | 0.120 |
Why?
| Tosyl Compounds | 1 | 2014 | 14 | 0.120 |
Why?
| Disease Models, Animal | 2 | 2021 | 3580 | 0.120 |
Why?
| Sarcoma, Ewing | 1 | 2015 | 62 | 0.120 |
Why?
| Genes, Reporter | 2 | 2012 | 257 | 0.120 |
Why?
| Ligands | 6 | 2023 | 569 | 0.110 |
Why?
| HEK293 Cells | 1 | 2016 | 602 | 0.110 |
Why?
| Protein Transport | 1 | 2015 | 400 | 0.110 |
Why?
| PTEN Phosphohydrolase | 1 | 2015 | 142 | 0.110 |
Why?
| In Situ Hybridization | 2 | 2010 | 298 | 0.110 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 941 | 0.110 |
Why?
| Cellular Reprogramming | 1 | 2014 | 84 | 0.110 |
Why?
| Cells, Cultured | 2 | 2016 | 3914 | 0.110 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 1993 | 45 | 0.110 |
Why?
| Cell Adhesion | 2 | 2012 | 433 | 0.110 |
Why?
| Ketones | 1 | 1993 | 44 | 0.110 |
Why?
| Neurotrophin 3 | 1 | 2012 | 11 | 0.110 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 332 | 0.110 |
Why?
| Mice, Inbred C57BL | 2 | 2016 | 4773 | 0.110 |
Why?
| Autocrine Communication | 1 | 2012 | 43 | 0.110 |
Why?
| Aromatase Inhibitors | 2 | 2014 | 49 | 0.100 |
Why?
| Nuclear Proteins | 5 | 2000 | 594 | 0.100 |
Why?
| Metalloendopeptidases | 1 | 1992 | 55 | 0.100 |
Why?
| Middle Aged | 6 | 2016 | 27014 | 0.100 |
Why?
| Cysteine Endopeptidases | 1 | 1992 | 61 | 0.100 |
Why?
| Transduction, Genetic | 1 | 2012 | 114 | 0.100 |
Why?
| Disease-Free Survival | 1 | 2014 | 621 | 0.100 |
Why?
| Gene Silencing | 2 | 2014 | 175 | 0.100 |
Why?
| Carrier Proteins | 2 | 2023 | 701 | 0.100 |
Why?
| Tumor Burden | 1 | 2012 | 261 | 0.100 |
Why?
| Tubulin | 1 | 2012 | 123 | 0.100 |
Why?
| Luciferases | 1 | 2012 | 140 | 0.100 |
Why?
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 5 | 0.100 |
Why?
| Receptors, Leptin | 1 | 2011 | 24 | 0.100 |
Why?
| Protein Biosynthesis | 2 | 2012 | 390 | 0.100 |
Why?
| Tissue Array Analysis | 2 | 2008 | 49 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2016 | 1805 | 0.100 |
Why?
| GTPase-Activating Proteins | 1 | 2011 | 71 | 0.090 |
Why?
| Fibronectins | 1 | 2011 | 108 | 0.090 |
Why?
| Enzyme Inhibitors | 2 | 2008 | 757 | 0.090 |
Why?
| Microfilament Proteins | 1 | 2011 | 126 | 0.090 |
Why?
| HeLa Cells | 5 | 2006 | 567 | 0.090 |
Why?
| Cell Transdifferentiation | 1 | 2010 | 31 | 0.090 |
Why?
| Retinoid X Receptors | 1 | 2010 | 39 | 0.090 |
Why?
| Inflammation | 1 | 2020 | 2499 | 0.090 |
Why?
| Cyclins | 3 | 1999 | 79 | 0.090 |
Why?
| Protein Isoforms | 4 | 2006 | 339 | 0.090 |
Why?
| Lung | 1 | 2022 | 3673 | 0.090 |
Why?
| Breast | 2 | 2022 | 138 | 0.090 |
Why?
| DNA, Complementary | 4 | 2008 | 258 | 0.090 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2010 | 317 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 930 | 0.080 |
Why?
| Cell Line, Transformed | 1 | 2009 | 133 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2016 | 2800 | 0.080 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 195 | 0.080 |
Why?
| Glucose | 1 | 2013 | 904 | 0.080 |
Why?
| Perilipin-1 | 1 | 2008 | 16 | 0.080 |
Why?
| Leiomyoma | 1 | 2008 | 45 | 0.080 |
Why?
| S100 Proteins | 1 | 2008 | 39 | 0.080 |
Why?
| Drug Interactions | 1 | 2009 | 347 | 0.070 |
Why?
| Hysterectomy | 1 | 2008 | 118 | 0.070 |
Why?
| Receptor, IGF Type 1 | 1 | 2006 | 58 | 0.070 |
Why?
| Survival Rate | 2 | 2020 | 1650 | 0.070 |
Why?
| Aged | 4 | 2016 | 19255 | 0.070 |
Why?
| Stem Cells | 1 | 2010 | 546 | 0.070 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 1008 | 0.070 |
Why?
| Molecular Sequence Data | 6 | 2010 | 2790 | 0.070 |
Why?
| Precancerous Conditions | 1 | 2006 | 156 | 0.060 |
Why?
| Obesity | 1 | 2017 | 2517 | 0.060 |
Why?
| Neoplasm Staging | 1 | 2008 | 1178 | 0.060 |
Why?
| Protein Binding | 4 | 2010 | 1917 | 0.060 |
Why?
| Thromboplastin | 1 | 2004 | 71 | 0.060 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 107 | 0.060 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 388 | 0.060 |
Why?
| Ovariectomy | 2 | 2017 | 117 | 0.060 |
Why?
| Postmenopause | 3 | 2017 | 300 | 0.060 |
Why?
| Amino Acid Sequence | 4 | 2010 | 2000 | 0.050 |
Why?
| Adult | 4 | 2016 | 30726 | 0.050 |
Why?
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 31 | 0.050 |
Why?
| Prognosis | 2 | 2020 | 3339 | 0.050 |
Why?
| Immune Evasion | 1 | 2022 | 47 | 0.050 |
Why?
| ErbB Receptors | 1 | 2005 | 557 | 0.050 |
Why?
| Larva | 2 | 1993 | 193 | 0.050 |
Why?
| Fibroblasts | 1 | 2006 | 839 | 0.050 |
Why?
| Biology | 1 | 2022 | 78 | 0.050 |
Why?
| Promegestone | 4 | 2005 | 33 | 0.050 |
Why?
| Treatment Outcome | 1 | 2015 | 9159 | 0.050 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 171 | 0.050 |
Why?
| Mifepristone | 2 | 2000 | 65 | 0.050 |
Why?
| Drug Resistance | 2 | 2000 | 162 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2004 | 503 | 0.050 |
Why?
| Young Adult | 1 | 2016 | 10487 | 0.050 |
Why?
| Mammals | 1 | 2022 | 251 | 0.050 |
Why?
| GPI-Linked Proteins | 1 | 2020 | 54 | 0.050 |
Why?
| Exons | 2 | 1999 | 300 | 0.050 |
Why?
| Antigens, Nuclear | 1 | 2000 | 19 | 0.040 |
Why?
| Adenocarcinoma | 1 | 2006 | 799 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2008 | 6419 | 0.040 |
Why?
| Postpartum Period | 1 | 2022 | 281 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 88 | 0.040 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1999 | 57 | 0.040 |
Why?
| Receptor Cross-Talk | 1 | 1998 | 20 | 0.040 |
Why?
| DNA Helicases | 1 | 2000 | 133 | 0.040 |
Why?
| p300-CBP Transcription Factors | 1 | 2018 | 15 | 0.040 |
Why?
| Immunological Synapses | 1 | 2018 | 18 | 0.040 |
Why?
| STAT1 Transcription Factor | 1 | 1998 | 64 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 155 | 0.040 |
Why?
| Drug Synergism | 1 | 1998 | 317 | 0.040 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 1998 | 181 | 0.040 |
Why?
| Oxygenases | 1 | 1997 | 9 | 0.040 |
Why?
| Cell Culture Techniques | 1 | 2020 | 344 | 0.040 |
Why?
| Biological Transport | 1 | 1998 | 375 | 0.040 |
Why?
| Receptor, ErbB-3 | 1 | 2017 | 42 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2020 | 1127 | 0.040 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 1998 | 277 | 0.040 |
Why?
| STAT3 Transcription Factor | 1 | 1998 | 174 | 0.040 |
Why?
| Carcinogens | 1 | 1997 | 105 | 0.040 |
Why?
| Ribosomal Proteins | 1 | 1997 | 70 | 0.040 |
Why?
| Analysis of Variance | 2 | 2005 | 1227 | 0.030 |
Why?
| Male | 2 | 2021 | 55967 | 0.030 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 336 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2020 | 924 | 0.030 |
Why?
| Steroids | 1 | 2017 | 147 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 1999 | 420 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 274 | 0.030 |
Why?
| Sequence Alignment | 2 | 2010 | 327 | 0.030 |
Why?
| Histones | 2 | 2014 | 540 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 347 | 0.030 |
Why?
| Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 16 | 0.030 |
Why?
| Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 16 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2017 | 1168 | 0.030 |
Why?
| Base Sequence | 3 | 2008 | 2114 | 0.030 |
Why?
| Keratin-5 | 1 | 2014 | 46 | 0.030 |
Why?
| Genetic Variation | 1 | 1999 | 880 | 0.030 |
Why?
| Nuclear Receptor Coactivator 1 | 2 | 2006 | 10 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 337 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2017 | 645 | 0.030 |
Why?
| Adipose Tissue | 1 | 2017 | 555 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 677 | 0.030 |
Why?
| Dipeptides | 1 | 1993 | 49 | 0.030 |
Why?
| DNA Primers | 2 | 2008 | 514 | 0.030 |
Why?
| Chromatography | 1 | 1992 | 24 | 0.030 |
Why?
| Microscopy, Electron | 1 | 1993 | 409 | 0.030 |
Why?
| Elastin | 1 | 1992 | 78 | 0.030 |
Why?
| Hydrolysis | 1 | 1992 | 179 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1992 | 101 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2020 | 4440 | 0.020 |
Why?
| Blotting, Northern | 1 | 2010 | 194 | 0.020 |
Why?
| Glycoproteins | 1 | 1992 | 309 | 0.020 |
Why?
| Oligopeptides | 1 | 1992 | 248 | 0.020 |
Why?
| Cell Size | 1 | 2010 | 81 | 0.020 |
Why?
| Cell Dedifferentiation | 1 | 2010 | 28 | 0.020 |
Why?
| COS Cells | 2 | 2003 | 175 | 0.020 |
Why?
| DNA, Helminth | 1 | 2010 | 16 | 0.020 |
Why?
| Collagen | 1 | 1992 | 415 | 0.020 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 74 | 0.020 |
Why?
| DNA Methylation | 1 | 2014 | 498 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2010 | 137 | 0.020 |
Why?
| Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.020 |
Why?
| Rats | 1 | 2017 | 5034 | 0.020 |
Why?
| Extracellular Matrix | 1 | 1992 | 439 | 0.020 |
Why?
| Phosphorylation | 2 | 2005 | 1571 | 0.020 |
Why?
| Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 2 | 2005 | 1870 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2008 | 80 | 0.020 |
Why?
| Myometrium | 1 | 2008 | 35 | 0.020 |
Why?
| Cell Division | 2 | 2000 | 759 | 0.020 |
Why?
| DNA, Neoplasm | 1 | 2008 | 157 | 0.020 |
Why?
| Androstadienes | 1 | 2008 | 97 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3467 | 0.020 |
Why?
| Sequence Analysis, DNA | 1 | 2010 | 732 | 0.020 |
Why?
| Trypan Blue | 1 | 2006 | 4 | 0.020 |
Why?
| Comet Assay | 1 | 2006 | 18 | 0.020 |
Why?
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 6 | 0.020 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2006 | 55 | 0.020 |
Why?
| Insulin Receptor Substrate Proteins | 1 | 2006 | 56 | 0.020 |
Why?
| Radiation, Ionizing | 1 | 2006 | 73 | 0.020 |
Why?
| Staining and Labeling | 1 | 2006 | 139 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2006 | 136 | 0.020 |
Why?
| Mutant Proteins | 1 | 2006 | 96 | 0.020 |
Why?
| Recombinant Fusion Proteins | 2 | 2000 | 616 | 0.020 |
Why?
| Androstenes | 1 | 2005 | 11 | 0.020 |
Why?
| Amino Acid Motifs | 1 | 2006 | 198 | 0.020 |
Why?
| Neuroblastoma | 1 | 2006 | 130 | 0.020 |
Why?
| Caspase 3 | 1 | 2006 | 237 | 0.020 |
Why?
| Medroxyprogesterone Acetate | 1 | 2005 | 29 | 0.020 |
Why?
| Levonorgestrel | 1 | 2005 | 32 | 0.020 |
Why?
| Desogestrel | 1 | 2005 | 40 | 0.020 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 327 | 0.020 |
Why?
| DNA Repair | 1 | 2006 | 190 | 0.020 |
Why?
| Alkaline Phosphatase | 1 | 2005 | 144 | 0.020 |
Why?
| Sucrose | 1 | 2004 | 91 | 0.010 |
Why?
| Insulin-Like Growth Factor I | 1 | 2006 | 281 | 0.010 |
Why?
| Adenosine Triphosphate | 1 | 2006 | 431 | 0.010 |
Why?
| DNA Damage | 1 | 2006 | 357 | 0.010 |
Why?
| Reactive Oxygen Species | 1 | 2006 | 549 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2006 | 804 | 0.010 |
Why?
| Microscopy, Confocal | 1 | 2004 | 299 | 0.010 |
Why?
| Mutagenesis | 1 | 2003 | 170 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 2003 | 352 | 0.010 |
Why?
| Progesterone Congeners | 1 | 2002 | 14 | 0.010 |
Why?
| Uterus | 1 | 2003 | 193 | 0.010 |
Why?
| Dimerization | 1 | 2002 | 177 | 0.010 |
Why?
| Cell Survival | 1 | 2004 | 1024 | 0.010 |
Why?
| Plasmids | 1 | 2002 | 345 | 0.010 |
Why?
| DNA-Activated Protein Kinase | 1 | 2000 | 11 | 0.010 |
Why?
| Ku Autoantigen | 1 | 2000 | 13 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 2006 | 1265 | 0.010 |
Why?
| Glutathione Transferase | 1 | 2000 | 95 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2003 | 1243 | 0.010 |
Why?
| Methionine | 1 | 2000 | 145 | 0.010 |
Why?
| Culture Techniques | 1 | 1999 | 80 | 0.010 |
Why?
| RNA | 1 | 2005 | 819 | 0.010 |
Why?
| Growth Substances | 1 | 1999 | 136 | 0.010 |
Why?
| Cricetinae | 1 | 1999 | 260 | 0.010 |
Why?
| Estrogen Receptor beta | 1 | 1999 | 35 | 0.010 |
Why?
| Peptide Fragments | 1 | 2003 | 675 | 0.010 |
Why?
| Phosphotyrosine | 1 | 1998 | 33 | 0.010 |
Why?
| Receptors, Growth Factor | 1 | 1998 | 49 | 0.010 |
Why?
| Premenopause | 1 | 1999 | 103 | 0.010 |
Why?
| Sp1 Transcription Factor | 1 | 1998 | 23 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 146 | 0.010 |
Why?
| Chromosome Mapping | 1 | 1999 | 489 | 0.010 |
Why?
| Estrogen Antagonists | 1 | 1998 | 39 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 147 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 165 | 0.010 |
Why?
| Isomerism | 1 | 1997 | 42 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 263 | 0.010 |
Why?
| Gene Deletion | 1 | 1999 | 355 | 0.010 |
Why?
| Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| Yeasts | 1 | 1997 | 51 | 0.010 |
Why?
| Autoantigens | 1 | 2000 | 398 | 0.010 |
Why?
| Blotting, Western | 1 | 1998 | 1153 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 1998 | 1001 | 0.010 |
Why?
| Time Factors | 1 | 2004 | 6165 | 0.010 |
Why?
| Cell Line | 1 | 1998 | 2651 | 0.010 |
Why?
| Models, Biological | 1 | 1998 | 1646 | 0.010 |
Why?
| Cytokines | 1 | 1999 | 1853 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|